CYP2C9 polymorphism analysis in Han Chinese populations: Building the largest allele frequency database

Pharmacogenomics Journal

Volumn 14, Issue 1, 2014, Pages 85-92

  Dai, D P ^a   Xu, R A ^b,c   Hu, L M ^b,d   Wang, S H ^b   Geng, P W ^b   Yang, J F ^e   Yang, L P ^e   Qian, J C ^b   Wang, Z S ^f   Zhu, G H ^f   Zhang, X H ^c   Ge, R S ^b,f   Hu, G X ^b   Cai, J P ^a  

^a BEIJING HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d TAIZHOU MUNICIPAL HOSPITAL   (China)

^e BEIJING HOSPITAL   (China)

^f THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

allelic variant; catalytic activity; CYP2C9; Han Chinese; polymorphism

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA;

ACCURACY; ARTICLE; CATALYSIS; CHINESE; CONTROLLED STUDY; CYP2C9 GENE; DNA POLYMORPHISM; EXON; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC DATABASE; GENETIC VARIABILITY; HUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL;

ALLELES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CERCOPITHECUS AETHIOPS; CHINA; COS CELLS; DATABASES, GENETIC; EXONS; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 84893644129     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.2     Document Type: Article

References (55)

1. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
2. Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structureactivity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009; 16: 3480-3675.
3. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010; 20: 277-281.
4. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2012; 27: 9-54.
5. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89-295.
6. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009; 10: 781-834.
7. Zuo J, Xia D, Jia L, Guo T. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie 2012; 67: 639-644.
8. Zuo LJ, Guo T, Xia DY, Jia LH. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers 2012; 16: 102-108.
9. Zhang W, Zhang WJ, Zhu J, Kong FC, Li YY, Wang HY et al. Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics 2012; 13: 309-321.
10. Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan HH et al. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genomics 2012; 22: 176-182.
11. Xiong Y, Wang M, Fang K, Xing Q, Feng G, Shen L et al. A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 2011; 97: 277-281.
12. Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int 2011; 207: 183-187.
13. Zhu J, Zhang W, Li Y, Wang H, Zheng W, Wang C. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. Pharmacogenomics 2010; 11: 113-119.
14. Li Z, Wang G, Wang LS, Zhang W, Tan ZR, Fan L et al. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009; 39: 788-793.
15. Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348: 57-61.
16. Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003; 17: 373-376.
17. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
18. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465-469.
19. Zhang YN, Cui W, Han M, Zheng B, Liu F, Xie RQ et al. [Gene polymorphism of CYP450 2C9 and VKORC1 in Chinese population and their relationships to the maintaining dosage of warfarin]. Zhonghua Liu Xing Bing Xue Za Zhi 2010; 31: 218-222.
20. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005; 35: 853-861.
21. Allabi AC, Gala JL, Horsmans Y. CYP2C9 CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15: 779-786.
22. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004; 76: 113-118.
23. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527-537.
24. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315: 1085-1090.
25. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77: 353-364.
26. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16: 497-514.
27. Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009; 3: 169-190.
28. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31: 1549-1557.
29. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 2010; 70: 393-399.
30. Wang HH, Liao YW, Chiang HL, Wu JY, Chen YT. Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population. Pharmacogenomics 2009; 10: 359-374.
31. Si D, Wang J, Zhang Y, Zhong D, Zhou H. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2. Biopharm Drug Dispos 2012; 33: 342-345.
32. Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008; 5: 171-173.
33. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104.
34. Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 2012; 27: 68-84.
35. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-219.
36. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 2003; 59: 707-709.
37. Lee HW, Lim MS, Lee J, Jegal MY, Kim DW, Lee WK et al. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther 2011; 37: 105-111.
38. Ngow HA, Wan Khairina WM, Teh LK, Lee WL, Harun R, Ismail R et al. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med J 2009; 50: 490-493.
39. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol 2005; 19: 101-105.
40. Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B. Frequencies of VKORC1 -1639 G4A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci Trends 2010; 4: 333-337.
41. Siddiqi A, Khan DA, Khan FA, Naveed AK. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population. Pak J Pharm Sci 2010; 23: 417-422.
42. Kuanprasert S, Dettrairat S, Palacajornsuk P, Kunachiwa W, Phrommintikul A. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. J Med Assoc Thai 2009; 92: 1597-1601.
43. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-791.
44. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-450.
45. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001; 79: 841-847.
46. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-387.
47. Sava V, Mosquera D, Song S, Cardozo-Pelaez F, Sanchez-Ramos JR. Effects of melanin and manganese on DNA damage and repair in PC12-derived neurons. Free Radic Biol Med 2004; 36: 1144-1154.
48. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005; 61: 491-497.
49. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2007; 21: 419-426.
50. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N et al. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis 2009; 43: 239-242.
51. Scordo MG, Caputi AP, DArrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50: 195-200.
52. Gra O, Mityaeva O, Berdichevets I, Kozhekbaeva Z, Fesenko D, Kurbatova O et al. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians. Genet Test Mol Biomarkers 2010; 14: 329-342.
53. Sanchez-Diz P, Estany-Gestal A, Aguirre C, Blanco A, Carracedo A, Ibanez L et al. Prevalence of CYP2C9 polymorphisms in the south of Europe. Pharmacogenomics J 2009; 9: 306-310.
54. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-631.
55. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415.